To further evaluate the effectiveness of KH‐4‐43 in the cisplatin‐resistant ovarian cancer context, we tested CRL4 inhibition in A2780cis cells, an established cisplatin‐resistant cell line. This evidence concerns the gene IL17RB and ovarian carcinoma.